A long-term study of DSP-5423 in pediatric patients with schizophrenia
Phase 3
Completed
- Conditions
- Schizophrenia
- Registration Number
- JPRN-jRCT2080221683
- Lead Sponsor
- Sumitomo Dainippon Pharma Co., Ltd.
- Brief Summary
We investigated the safety and efficacy of DSP-5423 4 to 24 mg / day for 52 weeks in pediatric schizophrenia subjects. The effectiveness of DSP-5423 was maintained even after long-term administration for schizophrenia in children, and there is no concern about safety and peculiar in children were observed.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 106
Inclusion Criteria
Patients who completed the confirmatory study etc.
Exclusion Criteria
Patients who fall under a contraindication listed in the LONASEN package insert.
Patients with Parkinson disease etc.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method